Mineral metabolism and bone abnormalities in children with chronic renal failure

Area of Science:

• Pediatric Nephrology
• Endocrinology
• Skeletal Biology

Background:

• Chronic renal failure (CRF) in children causes growth impairment linked to mineral metabolism disorders and bone disease.
• Key factors include hyperphosphatemia, hypocalcemia, metabolic acidosis, vitamin D/IGF alterations, and parathyroid dysfunction, leading to secondary hyperparathyroidism.
• The KDIGO conference recommends viewing chronic kidney disease-mineral bone disorder as systemic and standardizing bone histomorphometry (TMV).

Purpose of the Study:

• To review the complexities of mineral metabolism abnormalities and bone disease in pediatric chronic renal failure.
• To discuss diagnostic challenges, including the controversial use of DXA and the investigation of new imaging modalities.
• To outline current and future management strategies for these conditions in children.

Main Methods:

• Literature review and synthesis of current research on pediatric chronic kidney disease-mineral bone disorder.
• Analysis of diagnostic approaches, including histomorphometry and emerging skeletal imaging techniques.
• Evaluation of therapeutic interventions for mineral abnormalities and secondary hyperparathyroidism.

Main Results:

• Mineral and bone disorders significantly impact growth and skeletal health in children with CRF.
• DXA's utility is debated due to confounding factors like growth retardation and pubertal delay; new imaging methods are under investigation.
• Current management focuses on phosphate binders and vitamin D analogs, with ongoing research into calcimimetics and bisphosphonates.

Conclusions:

• Mineral metabolism abnormalities and bone disease are critical complications of pediatric chronic renal failure, affecting growth.
• Accurate assessment of bone health in these children is challenging, necessitating further research into advanced imaging techniques.
• Multifactorial management strategies are employed, with future therapies like calcimimetics and bisphosphonates requiring further clinical evaluation.